This report analyzes the worldwide markets for Anti-Obesity Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. The report profiles 59 companies including many key and niche players such as Arena Pharmaceuticals, Inc., AstraZeneca Plc., F.HOFFMANN-LA ROCHE LTD., GlaxoSmithKline Plc, Orexigen Therapeutics, Inc., and VIVUS, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Table 1: Leading Countries by Percentage of Obese Population (2010) (includes corresponding Graph/Chart)
Table 2: Obesity Rates (%) in OECD Countries (includes corresponding Graph/Chart)
Table 3: Obese and Overweight & Obese Population in the World (2010): Percentage Share Breakdown by Region for US, European Union, and Rest of World (includes corresponding Graph/Chart)
Table 4: Abdominal Obesity Prevalence (%) by Region and Sex (includes corresponding Graph/Chart)
Trends and Issues
Rising Demand for Obesity Therapeutics
Growing Emphasis on Metabolism
Barriers to Development of Effective Drugs
New Research Aids in Discovery of Novel Drugs
Growing Problem of Obesity in Asia Particularly China
Online Drug Stores Boost Sales
3. COMPETITION
Roche Leads the Race
Withdrawal of High-Revenue Generating Drugs Affects Competition Metrics
Table 5: Leading Brands in the Global Anti-obesity Drugs Market (2010): Percentage Share Breakdown of Revenues for Xenical/orlistat, Reductil/Meridia (sibutramine), Alli, and Others (includes corresponding Graph/Chart)
Table 6: Obesity Treatment Options and Corresponding Success Rate
6. ANTI-OBESITY DRUGS - AN INSIGHT
Introduction
Mechanism of Action
Review of Available Drugs
Phentermine
Sibutramine
Orlistat
Anti-obesity Drugs, Brands and Mechanism of Action
Table 7: Global Anti-obesity Prescription Drugs Market (2010): Percentage Share Breakdown of Prescriptions by Physician Practices - Primary Care Physicians (PCP), Internal Medicine, Obstetrics/ Gynecology, Endocrinology/Diabetes, Psychiatry/ Neurology, Cardiology and Others (includes corresponding Graph/Chart)
Review of Select Drugs Awaiting approval / Under Trials
7. PRODUCT APPROVALS/LAUNCHES
FDA Expert Panel Recommends Approval of Orexigen's Contrave
Orexigen Receives FDA Approval for Anti-Obesity Drug
European Commission Authorizes Sale of Orlistat without Prescription in the UK
Sanofi-Aventis Receives Swiss Approval for Acomplia
Zydus Cadila Introduces Slimona
Torrent Introduces Rimoslim
Gencor Introduces Slimaluma
Orexigen Develops Excalia
Scripps Research Institute Develops Vaccine for Obesity
Sanofi-Aventis Receives Approval to Market Obesity Drug in EU
Sanofi-Aventis Rolls Out Acomplia
Sanofi Secures Approval for Acomplia in the UK
Novo Nordisk to Develop Anti-obesity Drug
Sanofi-Aventis Receives Approval to Market Acomplia in Mexico
Ind-Swift Introduces Sibuslim-10
Wellnx Launches NV
Iron-Tek Introduces Appetite Suppressant
Yamanouchi and Keio University Discover Target Molecule for Developing Anti-obesity Drug
8. RECENT INDUSTRY ACTIVITY
Takeda Enters into Partnership with Florida Hospital and SBMRI
DCGI Bans Sale of R-Sibutramine and Sibutramine
Abbot Withdraws Meridia
Takeda and Amylin Halt Clinical Studies of Pramlintide/ Metreleptin Combination Therapy
Isis Includes ISIS-FGFR4Rx into Drug Development Pipeline
Arrowhead Establishes Ablaris Therapeutics
Orexigen Enters into Partnership with Takeda
Ventana and GTMC Enter into Distribution Agreement
Taisho and Glaxo Group Enter into an Agreement
PROLOR Inks Agreement with YRDCL
Aegis Enters into Joint Commercialization Agreement with Albany Medical College
Wyeth Pharmaceuticals Acquires Thiakis
9. CORPORATE INITIATIVES IN THE RECENT PAST - A PERSPECTIVE BUILDER
Pfizer Halts CP-945, 598 Development
Shionogi to Acquire Sciele Pharma
Anthill Inks Agreement with Zafgen
EMEA Suspends Acomplia
GlaxoSmithKline to Sell Alli as OTC Drug
Sanofi-Aventis to Market Acomplia in UK
Orexigen Receives 4th US Patent for Contrave
BELLUS Health to Acquire Innodia
Ore Secures License to Develop Romazarit
GlaxoSmithKline Receives FDA Approval for Orlistat
Pfizer Receives Approval for Slentrol
GlaxoSmithKline Secures Licensing Rights of Orlistat
Pfizer Collaborates with Bristol-Myers Squibb
Takeda Collaborates with LG Life Sciences
Takeda to Acquire Paradigm
Sanofi-Aventis Secures Reimbursement Status for Acomplia
AstraZeneca Inks Agreement with Palatin Technologies
Switzerland Includes Acomplia in Reimbursement List
Allergan Pockets EndoArt
Sanofi-Aventis Receives Approval for Acomplia in Brazil
Biocon Inks MoU with Neopharma
Aurigene Partners with Forest Laboratories
Genaera Initiates First Human Trial of Trodusquemine
Neurogen Completes First Trial of NGD-4715
Alizyme Secures USFDA Approval for Cetilistat Trials
GW Pharma to Start Human Trials of New Anti Obesity Drug
Epix Completes Phase Ib Trial of PRX-07034
7TM Pharma Starts Phase I/II Trial of TM30339
Pfizer Licenses Obesity Compounds from Bayer Pharmaceuticals
Merck Terminates Collaboration with Nastech
Sanofi-Aventis to Receive Rights for Rimonabant
UMN Pharma Inks Agreement with Crucell and DSM Biologics
7TM Pharma Pockets CareX SA
BioLineRx Inks Licensing Agreement with Yissum
Arena Starts Phase III Clinical Trials of Lorcaserin
Drug Induced Serotonin Could Promote Weight Loss
Takeda Initiates Phase II Clinical Trials of ALT-962
Glenmark to Commence Phase I Trial of New Anti-Obesity Drug
Amylin-Leptin Integrated Therapy to Treat Obesity
Vivus Completes Phase II Trial of Qnexa
VERNALIS Starts Phase I trial for Obesity
7TM Pharma Completes Phase I/ II Clinical Trials of TM30338
10. FOCUS ON SELECT PLAYERS
Arena Pharmaceuticals, Inc. (US)
AstraZeneca Plc (UK)
F. HOFFMANN-LA ROCHE LTD. (Switzerland)
GlaxoSmithKline Plc (UK)
Orexigen Therapeutics, Inc. (US)
VIVUS, Inc. (US)
11. GLOBAL MARKET PERSPECTIVE
Table 8: World Recent Past, Current & Future Market Analysis for Anti-Obesity Drugs by Geographic Region - US, Europe and Rest of World Independently Analyzed with Annual Sales Figures in US$ million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 9: World Historic Review for Anti-Obesity Drugs by Geographic Region - US, Europe and Rest of World Independently Analyzed with Annual Sales Figures in US$ million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 10: World 15-Year Perspective for Anti-Obesity Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Europe and Rest of World Markets for Years 2003, 2010 and 2017 (includes corresponding Graph/Chart)
12. THE UNITED STATES
A. Market Analysis
Market Overview
Table 11: Leading Product Segments in the US Weight Loss Market (2010): Percent Share Breakdown of Revenues for Diet Drinks, Health Clubs, Bariatric Surgery, Diet Foods, Artificial Sweeteners, Weight Loss Centers, Medically Supervised Programs, Meal Replacements & Appetite Suppressants, Prescription Drugs, Low Calorie Diet Programs and Others (includes corresponding Graph/Chart)
Obesity Catching Them Young
Key Statistics
Table 12: Obesity-Affected Population in the US (2010): Percentage Share Breakdown by Age Group (includes corresponding Graph/Chart)
Table 13: Proportion (%) of Obesity in the US Overweight Population by Age Group (includes corresponding Graph/Chart)
Table 14: Obesity and Overweight Prevalence in US Adults (2010) (includes corresponding Graph/Chart)
Table 15: Obesity Prevalence in US Adults by Type of Obesity (2010) (includes corresponding Graph/Chart)
State-wise Stats
Table 16: Top 20 US States by Obesity Rate (%) (2010) (includes corresponding Graph/Chart)
Table 17: US Obesity Prevalence Estimates and Forecasts (2006-2020) (includes corresponding Graph/Chart)
Reimbursement Scenario
Regulatory Environment
Insufficient Regulatory and Enforcement Laws
Obesity and Related Ailments: Burden on Societal and Economic Cost
Competition
Product Approval/Launches
Strategic Corporate Developments
Review of Major Players
B. Market Analytics
Table 18: US Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 19: US Historic Review for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ million for Years 2003 through 2008 (includes corresponding Graph/Chart)
13. EUROPE
A. Market Analysis
Market Overview
Obese Population in Europe
Table 20: Obese and Overweight & Obese Population in the European Union (2010): Percentage Share Breakdown by Age Group (includes corresponding Graph/Chart)
Table 21: Select EU Member Countries Ranked by Obesity Rates (2010) (includes corresponding Graph/Chart)
Table 22: Obesity Prevalence Rates (%) Among Adults by Gender (2010) (includes corresponding Graph/Chart)
Childhood Obesity Rates in EU
Focus on Select Players
B. Market Analytics
Table 23: European Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Geographic Region/Country - France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 24: European Historic Review for Anti-Obesity Drugs by Geographic Region/Country - France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Table 25: European 15-Year Perspective for Anti-Obesity Drugs by Geographic Region/Country - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2003, 2010 and 2017 (includes corresponding Graph/Chart)
13a. FRANCE
A. Market Analysis
Market Overview
Changing Lifestyle Alter Health Profile
Strategic Corporate Developments
B. Market Analytics
Table 26: French Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 27: French Historic Review for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
13b. GERMANY
Market Analysis
Table 28: German Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 29: German Historic Review for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
13c. ITALY
Market Analysis
Table 30: Italian Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 31: Italian Historic Review for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
13d. THE UNITED KINGDOM
A. Market Analysis
Market Overview
Strategic Corporate Developments
B. Market Analytics
Table 32: UK Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 33: UK Historic Review for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
13e. REST OF EUROPE
A. Market Analysis
Review of Select Markets
Spain
Belgium
The Netherlands
Finland
Sweden
Strategic Corporate Developments
B. Market Analytics
Table 34: Rest of Europe Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 35: Rest of Europe Historic Review for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
14. REST OF WORLD
A. Market Analysis
Brief Review of Select Regions
Asia-Pacific
Australia
Table 36: Prevalence Rate (%) of overweight/ obese Students in Australia (includes corresponding Graph/Chart)
China
India
Drugs Under Development by Indian Companies
Japan
Takeda Pharmaceutical Company Limited - A Key Player
Korea
Use of Diet Pills Lack Proper Monitoring
New Zealand
Strategic Corporate Developments
B. Market Analytics
Table 37: Rest of World Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 38: Rest of World Historic Review for Anti- Obesity Drugs Market Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
Anti-Obesity Drugs published by Global Industry Analysts, Inc. in October 1, 2011. This report consists of Pages: 365 and the price starts from US $ 4500.
The contents of this page may be different from the latest version. Please contact us for details.
